Risankizumab Tops Competitor for Clinical Remission in Moderate-to-Severe CD

Source link : https://www.newshealth.biz/health-news/risankizumab-tops-competitor-for-clinical-remission-in-moderate-to-severe-cd/

(MedPage Today) — SAN FRANCISCO — More adults with moderate-to-severe Crohn’s disease (CD) reached clinical remission after 6 months on risankizumab (Skyrizi) versus ustekinumab (Stelara), according to a head-to-head trial. In the phase III… Source link : https://www.medpagetoday.com/meetingcoverage/ccc/114142 Author : Publish date : 2025-02-08 19:03:49 Copyright for syndicated content belongs to the linked Source.

Author : News Health

Publish date : 2025-02-08 19:03:49

Copyright for syndicated content belongs to the linked Source.